Blog Posts
Follow along as we discuss the latest changes across the pharmaceutical, biotechnology, medical technology and life science sectors.
Regulation of In Vivo CAR‑T Therapies
Emerging Regulatory Frameworks for Programmable Immune Engineering Introduction In vivo CAR‑T therapy represents one of the most scientifically disruptive developments in modern biotechnology. Unlike traditional CAR‑T therapies, where T cells are removed from the patient, genetically engineered ex vivo, expanded, and reinfused, in vivo CAR‑T platforms aim to genetically program immune cells directly inside the…
From Sequential to Strategic
How Smart Biotech Companies Are Winning in Accelerated Global Approval Pathways The global biotechnology regulatory environment is no longer just accelerating, it is fragmenting into a set of strategic choices that materially impact time to market, capital efficiency, and valuation. Companies that actively design multi-market regulatory strategies early are gaining measurable advantages. Those that don’t…
Orphan and Rare Diseases in 2026
How Australia Accelerates Global Development A Maturing Global Rare Disease Landscape. In rare diseases, time equals patient impact. Leveraging Australia’s advantages enables faster, smarter global development. What are Orphan and Rare Diseases? Orphan and rare diseases are conditions that affect a small percentage of the population, often defined as impacting fewer than 1 in 2,000…
Hot Topics
Stay ahead of the curve with our Hot Topics section, where we spotlight the latest trends and conversations shaping the world of therapeutic goods right now.
Medsafe Rule of 2 Verification Pathway
Medsafe Rule of 2 Verification Pathway= Faster access to medicines The proposed Verification Pathway aims to accelerate market access for certain medicines by enabling Medsafe approval within 30 days, provided they’ve already been approved in two recognised overseas jurisdictions. This initiative is part of the Medicines Amendment Bill, now open for public consultation until 19…
Benefits of Bridging Clinical Trials in Australia
BRIDGING STUDIESDo you need to ‘Bridge’ the gap? When developing your global strategy, bridging trials play a crucial role in ensuring that data from one population can be effectively applied to another. The main objective of bridging clinical trials is to determine whether the results from clinical trials conducted in one population (e.g., Caucasian) can…
News Releases
Stay up to date with the latest news and industry developments in Australia/New Zealand and beyond.
The Adjutor Healthcare Group and Axis Health Co Announce a Strategic Partnership to Drive Client Success
Sydney, June 2024 – The Adjutor Healthcare Group and Axis Health Co are excited to announce their strategic partnership. This collaboration, which combines the unique strengths and expertise of two industry powerhouses, aims to provide enhanced consulting services and comprehensive solutions specifically tailored to the needs of each client, enabling them to achieve exceptional results.…
The Adjutor Healthcare Group Expands Global Presence with the Establishment of Adjutor Healthcare Hong Kong
Today marks a significant milestone for the Adjutor Healthcare Group, as we proudly announce the establishment of Adjutor Healthcare Hong Kong, further solidifying our commitment to excellence supporting global healthcare, development, regulatory and commercialisation needs.
Moderna mRNA COVID-19 Vaccine Approved in Australia
09 August, 2021 – Moderna mRNA COVID-19 Vaccine Approved The Therapeutic Goods Administration (TGA) has provisionally approved the Moderna mRNA COVID-19 vaccine for use in Australia, in record time. Australia’s fourth approved vaccine, one million doses are due to be released in the second half of September, 2021. The Spikevax (elasomeran) vaccine is provisionally approved…
Regulatory Announcements
Breaking news and updates about the regulation of therapeutic goods in Australia.
China Drug Regulation Updates 2026
China Drug Regulation Updates 2026 – Strategic Implications for International Biopharma and MedTech China has recently updated the implementing regulations under its Drug Administration Law. The changes reflect a continued shift toward encouraging pharmaceutical innovation while strengthening regulatory oversight across the full product lifecycle. On January 27, 2026, the State Council promulgated the revised “Regulations for the…
MEDSAFE NZ Moves Ahead in 2020
Since 2015, Medsafe NZ, the New Zealand Medicines and Medical Devices Safety Authority, has been working on a new therapeutic products regulatory regime to replace and modernise the regulatory arrangements for medicines, and provide regulation of all therapeutic products. Whilst we are still waiting for the progression of the Therapeutic Products Bill through parliament, the
Consumer Insecurity / Vanity Targeted by TGA – Massive Fines
The appearance of misleading terms and claims on websites and social media has attracted the attention of the TGA. The Therapeutic Goods Administration in Australia (TGA) has advised that fines were imposed via the Federal Court for misleading advertising by Peptide Clinics Australia (Peptide Clinics Pty Ltd), to the tune of $10 million (for breaches…